Tech Company Financing Transactions

Vedanta Biosciences Funding Round

Vedanta Biosciences closed a $60 million funding round on 8/6/2026. Backers included AMR Action Fund, BNP Paribas and Biomedical Advanced Research and Development Authority.

Transaction Overview

Company Name
Vedanta Biosciences
Announced On
8/6/2026
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors

AMR Action Fund (Lead Investor)

BNP Paribas (Lead Investor)

Biomedical Advanced Research and Development Authority

Proceeds Purpose
The company intends to use the funds to support its Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
19 Blackstone St.
Cambridge, MA 02139
USA
Phone
(857) 706-1427
Website
www.vedantabio.com
Email Address
[email protected]
Overview
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases.
Profile
Vedanta Biosciences LinkedIn Company Profile
Social Media
Vedanta Biosciences Company Twitter Account
Company News
Vedanta Biosciences News
Facebook
Vedanta Biosciences on Facebook
YouTube
Vedanta Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bernat Olle
  Bernat Olle LinkedIn Profile  Bernat Olle Twitter Account  Bernat Olle News  Bernat Olle on Facebook
Chief Financial Officer
Mark Mullikin
  Mark Mullikin LinkedIn Profile  Mark Mullikin Twitter Account  Mark Mullikin News  Mark Mullikin on Facebook
Chief Medical Officer
Jeffrey Silber
  Jeffrey Silber LinkedIn Profile  Jeffrey Silber Twitter Account  Jeffrey Silber News  Jeffrey Silber on Facebook
Chief Operating Officer
Daniel Couto
  Daniel Couto LinkedIn Profile  Daniel Couto Twitter Account  Daniel Couto News  Daniel Couto on Facebook
VP - Bus. Development
Taylor Feehley
  Taylor Feehley LinkedIn Profile  Taylor Feehley Twitter Account  Taylor Feehley News  Taylor Feehley on Facebook
VP - Finance
Maggie McGuigan
  Maggie McGuigan LinkedIn Profile  Maggie McGuigan Twitter Account  Maggie McGuigan News  Maggie McGuigan on Facebook
VP - Human Resources
Jack Kyte
  Jack Kyte LinkedIn Profile  Jack Kyte Twitter Account  Jack Kyte News  Jack Kyte on Facebook
VP - Manufacturing
Kris Ireland
  Kris Ireland LinkedIn Profile  Kris Ireland Twitter Account  Kris Ireland News  Kris Ireland on Facebook
VP - Operations
Lorraine Hughes
  Lorraine Hughes LinkedIn Profile  Lorraine Hughes Twitter Account  Lorraine Hughes News  Lorraine Hughes on Facebook
VP - Operations
Debra Winslow
  Debra Winslow LinkedIn Profile  Debra Winslow Twitter Account  Debra Winslow News  Debra Winslow on Facebook
VP - Regulatory Affairs
Anne Kuan
  Anne Kuan LinkedIn Profile  Anne Kuan Twitter Account  Anne Kuan News  Anne Kuan on Facebook
VP - Regulatory Affairs
Thomas O'Brien
  Thomas O'Brien LinkedIn Profile  Thomas O'Brien Twitter Account  Thomas O'Brien News  Thomas O'Brien on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/5/2026: conmeet venture capital transaction
Next: 8/6/2026: Factbird venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to record tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2026. Gaebler Ventures. All rights reserved.